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Abstract
Purpose: Cell division cycle 20 (CDC20) homolog is an anaphase-promoting complex activator that is essential for
cell division, but whether its expression in pancreatic ductal adenocarcinoma (PDAC) is significant is unknown. In
this retrospective study, we determined whether aberrant CDC20 expression can be used as a biomarker in
pancreatic ductal adenocarcinoma (PDAC) tumorigenesis and whether its expression reflects clinical progression.
Experimental design: We compared CDC20 expression levels in normal, cancerous, and inflamed pancreatic
tissues from stage II PDAC patients with clinical outcomes and determined CDC20 levels in seven PDAC cell lines.
CDC20 was identified using a cDNA microarray database containing gene expression profiles for PDAC tissues and
cell lines and chronic pancreatitis and normal pancreas tissues. Its expression was confirmed by real-time
quantitative reverse-transcriptase-polymerase chain reaction (qRT-PCR). An immunohistochemical analysis of tissue
microarrays from resected PDAC tumors and paired benign pancreatic tissues was done and CDC20 levels were
correlated with clinical outcome.
Results: Fifty-six patients were included in this study. A microarray analysis revealed 5-fold higher CDC20
expression in PDAC tissue than in chronic pancreatitis tissue. A qRT-PCR analysis confirmed a mean 20-fold higher
CDC20 level in PDAC tissue than in normal pancreas and pancreatitis tissue. RNA and protein CDC20 expression
was detected in several PDAC cell lines. An immunohistochemical analysis revealed higher CDC20 protein
expression levels in PDAC tissue than in normal pancreas tissue, and high CDC20 expression was associated with
poor differentiation (P = 0.020) and a significantly lower 5-year recurrence-free survival rate (P = 0.039); we also
found a trend toward a shorter overall survival duration.
Conclusions: Aberrant CDC20 expression may play an important role in PDAC tumorigenesis and progression and
may thus be useful as a marker of disease progression and prognosis and as a therapeutic target.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer death in the United States [1]:
the annual number of associated deaths is similar to the
disease’s annual incidence [2]. Similar statistics are
reported from other countries. For example, a recent
evaluation of the Finnish Cancer Registry, which
recorded 4922 patients with pancreatic cancer between
1990 and 1996, revealed that only 89 (1.8%) had sur-
v i v e da sl o n ga s5y e a r s[ 3 ] .S o m ee x c i t i n gp r o g r e s s e s
have been made for pancreatic cancer; however, there
haven’t been any breakthrough treatments [4-7]. Pan-
creatic cancer’s poor prognosis is associated with
increased cell proliferation and abnormal cell-cycle regu-
lation, although the mechanism and characteristics of
this cell growth have not been determined. Thus, prog-
nostic biomarkers and an understanding of their
mechanisms are urgently needed to enable further
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marker candidate, cell division cycle 20 homolog
(CDC20), is a regulatory protein that is a target mole-
cule in the cell-cycle checkpoint [8].
CDC20 [8] is a component of the mammalian cell-
cycle mechanism that activates the anaphase-promoting
complex (APC). Its expression is essential for cell divi-
sion, and its protein activity may be controlled by a bal-
ance between ubiquitination and de-ubiquitination. APC
activation is required for anaphase initiation and mitosis
exit. It is activated during mitosis and G1 phase by
CDC20 and HCDH1 [9-14]; these proteins directly bind
to APC and activate its cyclin ubiquitination activity. In
HeLa cells, CDC20 protein levels and CDC20-APC
binding peak in mitosis and decrease drastically in early
G1 phase.
Researchers assumed that the CDC20-Mad2-BubR1
complex is short lived and that inactivation of the spin-
dle-assembly checkpoint (SAC) passively releases
CDC20 from its inhibitors. However, structural studies
of Mad2-CDC20 interaction indicate that Mad2 binds
tightly to CDC20 [10-14]. Thus, the release of CDC20
from Mad2 may be an active process. When UbcH10
was added to extracts from cells with an active spindle-
assembly checkpoint, the APC/C became active, coinci-
dent with CDC20 ubiquitination and Mad2 and BubR1
dissociation [10]. The APC/C and CDC20 complex
(APC/CCDC20) is the most downstream target of the
SAC [5,7]. Moreover, in theS A C ,C D C 2 0i sac r i t i c a l
molecule: it activates the APC and helps dividing cells
proceed toward anaphase. CDC20 is highly expressed in
many tumor cells, where it results in chromosomal
instability. Limited studies have been performed of the
mechanism of SAC’s response to genotoxic stress. Ecto-
pically expressed p53 or DNA damage-induced endo-
genous p53 may transcriptionally downregulate CDC20
[12].
High CDC20 expression has been reported in various
malignancies [13-16] and many tumor cells [1,14,17,18],
including pancreatic cancer cells [15]. However, its clini-
cal significance in human pancreatic cancer is still
unknown. Using a cDNA microarray analysis, we noted
a 5-fold higher CDC20 expression in PDAC tissue when
compared to expression levels in normal pancreas or
chronic pancreatitis tissue (unpublished results). These
findings suggest that CDC20 may play an important role
in tumor development.
The purpose of this study was to determine the signif-
icance of aberrant CDC20 expression in PDAC tumori-
genesis and progression and whether it will be useful as
a biomarker for survival and as a therapeutic target. We
compared CDC20 RNA and protein expression in nor-
mal, cancerous, and inflamed pancreatic tissue from
PDAC patients and compared them with clinical
outcomes. We also evaluated CDC20 expression in
PDAC cell lines. Our findings suggest that high CDC20
expression is a biomarker for differentiation and recur-
rence-free survival, which indicate that aberrant CDC20
expression may play an important role in PDAC tumori-
genesis and progression and may thus be useful as a
marker of disease progression and prognosis and as a
therapeutic target.
Materials and methods
Patients and tissue samples
For real-time quantitative reverse transcription-polymer-
ase chain reaction (qRT-PCR), we isolated RNA from
fresh-frozen samples (five normal pancreatic tissue sam-
ples, five pancreatitis tissue samples, six PDAC tissue
samples) that had been collected during surgery and
stored in the Department of Pathology at The University
of Texas MD Anderson Cancer Center (Houston,
Texas).
Case selection for tissue microarray
We searched the patient record database at MD Ander-
son to identify patients with stage II PDAC who had
undergone pancreaticoduodenectomies between 1990
and 2005 and had not undergone any form of preopera-
tive chemotherapy or radiation therapy. Patients who
had undergone preoperative chemotherapy or radiation
therapy and those who had died from postoperative
complications were excluded from our study. This study
was approved by the MD Anderson institutional review
board.
Fifty-six patients were included in this study: 39 men
and 17 women (median age, 63.7 years [range, 39.8-79.9
years]). Patients’ follow-up information through Septem-
ber 2006 was extracted from the medical records and if
necessary, updated from a review of the U.S. Social
Security Index. Disease recurrence information was
updated at each follow-up visit. The recurrence-free sur-
vival duration was calculated as the time between the
surgery date and first recurrence (if disease recurred) or
last follow-up (if disease did not recur) date. Overall
survival duration was calculated as the diagnostic biopsy
or surgery (if biopsy was not diagnostic) date to death
or last follow-up (if death had not occurred) date.
Tissue microarrays
To construct the tissue microarrays used in this study,
we fixed human tissue samples in formalin and
embedded them in paraffin. Archival tissue blocks and
their matching hematoxylin-and eosin-stained slides
were retrieved, reviewed, and screened by a gastrointest-
inal pathologist (H.W.) to identify representative tumor
regions and non-neoplastic pancreatic parenchyma. For
each patient, two cores of tumor and two cores of
paired benign pancreatic tissue were sampled from
representative areas using a 1.0-mm punch. The tissue
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(Beecher Instruments, Sun Prairie, WI), as described
previously [19].
Cell culture
We determined CDC20 RNA expression in seven pan-
creatic cancer cell lines (Panc-48, PANC-1, AsPC-1,
CFPAC-1, Panc-3, Panc-28, and Capan-2). All cell
lines were maintained in Iscove’s modified Dulbecco’s
medium (Life Technologies, Grand Island, NY) con-
taining 10% fetal bovine serum, 2 mM L-glutamine, 50
U/mL penicillin, and 50 mg/mL streptomycin and
were maintained in a humidified incubator with 5%
CO2 at 37°C.
RNA extraction, cDNA preparation, and RT-PCR analysis
Total RNA was isolated from cell lines and tissue sam-
ples with TRIzol reagent (Invitrogen Life Technologies,
Carlsbad, CA), according to the manufacturer’s instruc-
tions. To measure CDC20 expression, quantitative real-
time RT-PCR was performed (sense 5’-GGCACCAGT-
GATCGACACATTCGCAT-3’;a n t i s e n s e5 ’-GCCA-
TAGCCTCAGGGTCTCATCTGCT-3’)[ 9 ] .P C Rw a s
performed under the following conditions: an initial
cycle of denaturation at 94°C for 2 minutes, followed by
21-23 cycles of denaturation at 92°C for 45 seconds;
annealing at 60°C for 60 seconds; extension at 72°C for
60 seconds; and a final extension at 72°C for 5 minutes.
PCR reactions were carried out using a Bio-Rad iCycler
iQ5 real-time PCR system (Certified GeneTool, Inc.,
Milpitas, CA). The 285-bp PCR products were con-
firmed by agarose gel electrophoresis. As an internal
control, we tested the housekeeping gene, ribosomal
protein S6 (RPS6), with the primers of RPS6-F (sense 5’-
AAGGAGAGAAGGATATTCCTGGAC-3’)a n dR P S 6 - R
(antisense 5’-AAGGGCTTTCTTACAACATACTGG-3’).
T h ep r i m e rp a i r sw e r ed e s i g n e dt og e n e r a t eaD N A
fragment spanning an exon-exon junction for RT-PCR
analysis.
Immunohistochemical CDC20 analysis
Immunohistochemical staining for CDC20 was per-
formed on 4-μm unstained sections from tissue microar-
ray blocks using a mouse monoclonal antibody against
CDC20 (Santa Cruz, CA). To determine antigenicity, we
treated tissue sections at 100°C in a steamer containing
10 mM citrate buffer (pH 6.0) for 60 minutes. The sec-
tions were then immersed in methanol containing 0.3%
hydrogen peroxidase for 20 minutes to block endogen-
ous peroxidase activity and incubated in 2.5% blocking
serum to reduce nonspecific binding. Sections were
incubated for 60 minutes at 37°C with primary anti-
CDC20 at a 1:200 dilution. A standard avidin-biotin
immunohistochemical analysis of the sections was per-
formed according to the manufacturer’s recommenda-
tions (Vector Laboratories, Burlingame, CA). Vector red
was used as a chromogen, and hematoxylin was used for
counterstaining.
Image analysis of immunohistochemical signaling
The staining results were evaluated independently by
two gastrointestinal pathologists (H.W. and Y.M.). We
quantified the percentage of positive cells in each core
using the Ariol automated image analysis system
(Genetix Corp., San Jose, CA). High CDC20 expression
was defined as nuclear staining of ≥ 4.93% of tumor
cells, whereas low expression was defined as nuclear
staining of < 4.93% of tumor cells or no nuclear staining
on the basis of the 75th percentile.
Statistical analysis
Fisher’s exact tests were used to compare categorical
data. One-way analysis of variance was used to compare
the quantitative real-time PCR data. Overall and recur-
rence-free survival probability curves were constructed
using the Kaplan-Meier method, 95% confidence interval
of patient survival and the log-rank test was used to
evaluate the statistical significance of differences.
We performed a univariate Cox regression analysis to
determine the prognostic significance of patients’ clinical
and pathologic characteristics. Cox proportional hazards
models were fitted for the multivariate analysis. After
the interactions between variables had been evaluated, a
backward stepwise procedure was used to derive the
best-fitting model. The statistical analysis was performed
using Statistical Package for Social Sciences software
(Macintosh 17.0; SPSS, Inc., Chicago, IL). We used a
two-sided significance level of 0.05 for all statistical
analyses.
Results
CDC20 mRNA expression was significantly higher in PDAC
tissue and PDAC cells lines than in normal pancreas and
pancreatitis tissue
We used qRT-PCR to determine CDC20 transcript
levels in five normal pancreatic tissue samples, five pan-
creatitis tissue samples, six PDAC tissue samples, and
seven pancreatic cancer cell lines (Panc-48, Panc-1,
AsPC-1, CFPac-1, Panc-3, Panc-28, and Capan-2).
CDC20 mRNA expression was significantly higher in
pancreatic cancer tissues (by 21.98-fold) and all expo-
nentially growing cell lines (by 57.68-fold) than in nor-
mal pancreas and pancreatitis tissue (Table 1). Post hoc
tests revealed no significant differences in CDC20
mRNA levels between normal pancreas and pancreatitis
tissues (P = 0.420) or PDAC tissues and cell lines (P =
0.120). However, we found significant differences
between normal pancreas and PDAC tissues (P < 0.001),
normal pancreas tissue and cell lines (P < 0.001), pan-
creatitis and PDAC tissues (P < 0.001), and pancreatitis
tissues and cell lines (P < 0.001).
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We performed immunohistochemical analyses of tumor
tissue and paired benign pancreatic tissue from 56
patients with stage II PDAC. We found extremely low
CDC20 protein levels in benign ductal pancreatic tissue
(Figure 1d) and much higher levels in PDAC tissue (P =
0.048) (Table 2 and Figure 1a-c).
We compared CDC20 protein expression levels in
PDAC tissue samples with patient age; tumor size, dif-
ferentiation, stage, and margin; lymph node metastasis;
and disease recurrence. As shown in Table 3, only
tumor differentiation was significantly associated with
CDC20 protein expression levels (P = 0.020). High
CDC20 protein expression in PDAC tissue was asso-
ciated with poor differentiation (Figure 1c), and low
expression was associated with well and moderate differ-
entiation (Figure 1b).
High CDC20 protein expression is associated with poor
recurrence-free survival rates in PDAC patients
The cutoff point was set as 4.93% of positive cells with
CDC20 protein expression. High CDC20 expression was
associated with a significantly lower 5-year recurrence-
free survival rate (P = 0.039; Table 4; Figure 1f): 28.57%
in patients with low expression versus 14.29% in those
with high expression. Patients with low CDC20 expres-
sion had a mean survival duration of 45.9 months (95%
confidence interval, 26.9-64.9 months), whereas those
with high expression had a mean survival duration of
15.6 months (1.8-29.4 months). The trend of the overall
survival curve indicates that PDAC patients with high
CDC20 expression have a poor overall survival rate;
however, because of the small patient sample in our
study, this association was not statistically significant
(Figure 5e).
Discussion
In this study, we found higher CDC20 mRNA expres-
sion in human PDAC cell lines and primary PDAC tis-
sues than in normal pancreas tissue from PDAC
patients. CDC20 protein over-expressions in human
PDAC tissue samples correlated with poor morphologi-
cal differentiation and short recurrence-free survival of
stage II PDAC patients. Based on the role of CDCD20
in regulating mitosis and cell growth [9-11] our findings
suggest that CDC20 expression may has a role in main-
taining human PDAC cell mitosis and thus facilitating
tumor growth.
CDC20 is a regulatory protein, interacting with several
other proteins at multiple points in the cell cycle. It is
required for two microtubule-dependent processes:
nuclear movement prior to anaphase and chromosome
separation. As with many other aspects of cell-cycle
control, CDC20 degradation is a conserved part of the
SAC from yeast to mammals. From its destruction pro-
file, CDC20 can be classified as an early mitotic sub-
strate of the APC/C, as it is degraded during
prometaphase, along with cyclin A and Nek2A, even
when the SAC is active. Clearly, CDC20’s essential func-
tion is to activate the APC/C; thus, during unperturbed
mitosis, CDC20 protein levels must be maintained [20].
We found high CDC20 RNA and protein expression
in PDAC tissue. Thus, a mechanism may exist that
involves upregulation of CDC20 RNA production and
downregulation of CDC20 protein degradation. Because
we did not evaluate CDC20 DNA levels in this study,
we could not determine CDC20 region chromosome
amplification levels. However, CDC20 expression is sup-
pressed by p53- and p21-dependent genotoxic stresses
through cell-cycle-dependent element/cell-cycle gene
homology region elements in the CDC20 promoter [16],
which may explain CDC20 overexpression. High CDC20
RNA expression in PDAC cells may be induced by
mutations of tumor suppressor genes such as p53 and
p21. CDC20 is continually synthesized in mitosis and
activates the APC/C. However, in the presence of
improperly attached kinetochores, Mad2 binds CDC20,
which allows it to load onto BubR1. After BubR1 has
bound to CDC20, Mad2 is no longer required to sustain
the binding and leaves the complex before or after the
complex is presented to the APC/C. The APC/C then
promotes CDC20 ubiquitylation and degradation to
sustain the checkpoint [21]. Given the evidence of an
APC/C and CDC20 loop [21], our data suggest that
high CDC20 levels in PDAC are due to a dysfunction
in APC/C-promoted CDC20 ubiquitylation and
degradation.
As shown in Table 3, quantitative CDC20 protein
expression levels were significantly associated with
PDAC tumor differentiation (P = 0.020). Therefore,
CDC20 may be a marker for PDAC disease progression.
High CDC20 levels appear to be associated with sev-
eral other cancers, including serous epithelial ovarian
cancer [15], gastric cancer [14], oral cancer [22], and
adult T-cell leukemia [23]; high levels are also found in
Table 1 Quantitative RNA CDC20 expression in human
PDAC tissue and cell lines
Sample N Relative value ΔCt
a P
b
Normal pancreas 5 1.00 15.70 ± 1.04 -
Pancreatitis 5 1.74 14.90 ± 1.50 0.42
PDAC tissue 6 21.98 11.24 ± 1.87 0.001
PDAC cell lines
c 7 57.68 9.85 ± 1.52 0.001
a. The difference of cycle number at the threshold level of CDC20 expression;
Mean ± Standard deviation
b. one-way ANOVA, pair-wise multiple comparisons test by Student-Newman-
Keuls vs. normal pancreas.
c. See Materials and Methods for a list of cell lines used here
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Page 4 of 7Figure 1 Association between CDC20 expression and PDAC patient survival.( a) A human PDAC tissue microarray was stained with anti-
CDC20 antibody (100×). (b) Well-differentiated malignant pancreatic duct with positive CDC20 signaling (400×). (c) Poorly differentiated PDAC
tissue with positive CDC20 signaling (400×). (d) Benign duct with negative CDC20 signaling 400×. (e) CDC20 expression was not associated with
overall survival in PDAC patients. (f) CDC20 expression was associated with recurrence-free survival in PDAC patients. Upper curve, patients with
low CDC20 expression; lower curve, patients with high CDC20 expression.
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the HT29 human adenocarcinoma cell line [13].
CDC20 overexpression has been detected in pancrea-
tic cancer tissue [24] and cell lines [25]. In this study,
we also evaluated its association with clinical outcomes.
We compared survival rates among PDAC patients
whose tumors expressed different CDC20 levels, as
assessed by a 4.93% cut-off point (75th percentile of the
CDC20 score) for CDC20-positive cells. We found a sta-
tistically significant difference in the 5-year recurrence-
free survival rate between patients with low and high
CDC20 expression (28.57% versus 14.29%; P = 0.039),
suggesting that CDC20 expression can be used as a
prognostic marker and therapeutic target. We also
found a trend towards a poorer overall survival rate in
patients with high CDC20 expression; this finding
should be evaluated further in a larger study population
to determine its significance.
We compared CDC20 expression in PDAC tissue with
that in normal pancreatic tissue. We found no signifi-
cant association between high CDC20 expression and
lymph node metastasis; tumor size, stage, or margin; or
patient age.
There have been development of inhibitors to some of
the key intracellular molecules, kinases, e.g., MDM2
(murine double minute 2), ALK (anaplastic lymphoma
kinase) and PARP (poly [ADP-ribose] polymerase) as
anti-cancer therapeutics [26]. Some of these, for exam-
ple ALK or PARP inhibitors are already in clinical use.
CDC20 could be a potential target for development of
anti-cancer agents.
Our results indicate that high CDC20 expression plays
an important role in promoting PDAC tumorigenesis.
CDC20 may be useful as a marker for disease progres-
sion and prognosis and as a therapeutic target that
could benefit PDAC patients.
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Table 2 CDC20 protein expression in PDAC and normal
tissue samples
Patient samples N CDC20 expression
a P
b
Cancer tissue 56 6.08 ± 11.16 0.048
Benign ductal tissue 53 2.11 ± 2.28
a. The percentage of positive cells with CDC20 protein expression; Mean ±
Standard deviation
b. Student’s t-test; cancer tissue versus benign tissue.
Table 3 Association between clinicopathologic
characteristics and CDC20 expression
Patient and tumor characteristic N CDC20 expression
h P
Age (years)
< 60 17 8.93 ± 17.29 0.449
a
60-70 24 4.54 ± 6.68
> 70 15 5.32 ± 7.72
Lymph node metastasis
Present 39 6.54 ± 12.86 0.646
b
Absent 17 5.03 ± 5.78
Tumor size (cm)
≤2.0 10 2.98 ± 3.10 0.314
c
> 2.0 43 7.05 ± 12.50
Unknown 3 2.50 ± 3.38
Tumor differentiation
Well or moderate 41 4.01 ± 5.93 0.020
d
Poor 15 11.76 ± 18.48
Tumor stage
IA and IB 1 19.02 ± N/A
IIA 16 4.16 ± 4.66 0.482
e
IIB 37 6.56 ± 13.18
IV 2 6.15 ± N/A
Tumor margin
Negative 45 6.09 ± 11.72 0.993
f
Positive 11 6.06 ± 8.96
Tumor recurrence
None 12 4.76 ± 5.33 0.308
g
Local and regional 12 2.39 ± 1.97
Metastasis 32 7.96 ± 14.14
a. Age range, < 60 versus 60-70 versus > 70 (one-way ANOVA).
b. Lymph node metastasis, present versus absent (Student’s t-test).
c. Tumor size, ≤ 2.0 cm versus > 2.0 cm (Student’s t-test)
d. Differentiation grade, well or moderate versus poor (Student’s t-test).
e. Tumor stage, IIA versus IIB (Student’s t-test).
f. Tumor margin, negative versus positive (Student’s t-test).
g. Tumor recurrence, no recurrence versus local and regional recurrence
versus metastasis (one-way ANOVA).
h. The percentage of positive cells with CDC20 protein expression; Mean ±
Standard deviation
Table 4 Five-year recurrence-free survival of PDAC
patients according to CDC20 expression level
CDC20
expression
a
N 5-year
survival
rate (%)
Mean survival duration,
months (95% confidence
interval)
P
b
Low 42 28.57 45.9 (26.9-64.9) 0.039
High 14 14.29 15.6 (1.8-29.4)
a. The percentage of positive cells with CDC20 protein expression; cut off
value is 4.93%
b. log-rank (Kaplan-Meier) test, low versus high.
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